{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:08:46Z","timestamp":1790784526292,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejca.2023.112965","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T17:01:31Z","timestamp":1688576491000},"page":"112965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients"],"prefix":"10.1016","volume":"191","author":[{"given":"Yu-Jing","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Chuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9528-3837","authenticated-orcid":false,"given":"Bin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-3648","authenticated-orcid":false,"given":"Ji-Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5109-0809","authenticated-orcid":false,"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Yuan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Ping","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Quan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-9159","authenticated-orcid":false,"given":"Jiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Qiang","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2023.112965_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2023.112965_bib2","first-page":"59","article-title":"Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): an update on 26 trials and 7080 patients","volume":"32","author":"Blanchard","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.112965_bib3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","article-title":"What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis","volume":"35","author":"Ribassin-Majed","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2023.112965_bib4","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijrobp.2019.06.2549","article-title":"The association between the development of radiation therapy, image technology, and chemotherapy, and the survival of patients with nasopharyngeal carcinoma: a cohort study from 1990 to 2012","volume":"105","author":"Sun","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ejca.2023.112965_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","article-title":"Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial","volume":"13","author":"Chen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.112965_bib6","article-title":"Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomised controlled trial","author":"Chan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.112965_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1525-1578(10)60642-3","article-title":"Molecular diagnosis of Epstein-Barr virus-related diseases","volume":"3","author":"Gulley","year":"2001","journal-title":"J Mol Diagn"},{"issue":"24","key":"10.1016\/j.ejca.2023.112965_bib8","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.ejca.2023.112965_bib9","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1200\/JCO.2006.07.7982","article-title":"Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma","volume":"24","author":"Leung","year":"2006","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2023.112965_bib10","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1200\/JCO.2012.46.0816","article-title":"Prospective study of tailoring whole-body dual-modality [18F] fluorodeoxyglucose positron emission tomography\/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging","volume":"31","author":"Tang","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.112965_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002642","article-title":"Prognostic value of plasma Epstein\u2013Barr Virus DNA for local and regionally advanced nasopharyngeal carcinoma treated with cisplatin-based concurrent chemoradiotherapy in intensity-modulated radiotherapy era","volume":"95","author":"Chen","year":"2016","journal-title":"Medicine"},{"issue":"8","key":"10.1016\/j.ejca.2023.112965_bib12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.112965_bib13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ejca.2023.112965_bib14","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","article-title":"Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes","volume":"23","author":"Comoli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2023.112965_bib15","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus\u2013targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.112965_bib16","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","article-title":"Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study","volume":"18","author":"Chandran","year":"2017","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2023.112965_bib17","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2023.112965_bib18","doi-asserted-by":"crossref","DOI":"10.4161\/23723556.2014.976507","article-title":"Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"4","author":"Li","year":"2015","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.ejca.2023.112965_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcrc.2005.04.005","article-title":"Randomisation and allocation concealment: a practical guide for researchers","volume":"20","author":"Doig","year":"2005","journal-title":"J Crit Care"},{"issue":"6","key":"10.1016\/j.ejca.2023.112965_bib20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5732\/cjc.011.10376","article-title":"Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy","volume":"31","author":"He","year":"2012","journal-title":"Chin J Cancer"},{"issue":"818450","key":"10.1016\/j.ejca.2023.112965_bib21","article-title":"A portable and cost-effective microfluidic system for massively parallel single-cell transcriptome profiling","author":"Chuanyu Liu","year":"2019","journal-title":"bioRxiv preprint"},{"issue":"7","key":"10.1016\/j.ejca.2023.112965_bib22","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ejca.2023.112965_bib23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","article-title":"DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors","volume":"8","author":"McGinnis","year":"2019","journal-title":"Cell Syst"},{"key":"10.1016\/j.ejca.2023.112965_bib24","unstructured":"Gennady Korotkevich VSNB. Fast gene set enrichment analysis. bioRxiv preprint (060012)."},{"issue":"1\u20132","key":"10.1016\/j.ejca.2023.112965_bib25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cell.2018.12.034","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"176","author":"Sade-Feldman","year":"2019","journal-title":"Cell"},{"issue":"28","key":"10.1016\/j.ejca.2023.112965_bib26","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomised phase II trials and a proposal for phase II screening trials","volume":"23","author":"Rubinstein","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7\u20138","key":"10.1016\/j.ejca.2023.112965_bib27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41434-020-0163-7","article-title":"An overview of development in gene therapeutics in China","volume":"27","author":"Wang","year":"2020","journal-title":"Gene Ther"},{"issue":"7\u20138","key":"10.1016\/j.ejca.2023.112965_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41434-020-0184-2","article-title":"Spotlight on gene therapy in China","volume":"27","author":"Ding","year":"2020","journal-title":"Gene Ther"},{"issue":"4","key":"10.1016\/j.ejca.2023.112965_bib29","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomised Intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol"},{"issue":"10297","key":"10.1016\/j.ejca.2023.112965_bib30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"398","author":"Chen","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejca.2023.112965_bib31","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1001\/jamaoncol.2022.4656","article-title":"Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a randomized clinical trial","volume":"8","author":"Miao","year":"2022","journal-title":"Jama Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.112965_bib32","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ejca.2023.112965_bib33","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.ejca.2023.112965_bib34","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","article-title":"Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"6522","key":"10.1016\/j.ejca.2023.112965_bib35","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.ejca.2023.112965_bib36","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-13-0380","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","volume":"19","author":"Besser","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2023.112965_bib37","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","article-title":"Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.ejca.2023.112965_bib38","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2023.112965_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100332","article-title":"Adoptive transfer of TILs plus anti-PD1 therapy: an alternative combination therapy for treating metastatic osteosarcoma","volume":"25","author":"Wang","year":"2020","journal-title":"J Bone Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.112965_bib40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"issue":"17","key":"10.1016\/j.ejca.2023.112965_bib41","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1200\/JCO.2012.46.6441","article-title":"Randomised selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma","volume":"31","author":"Dudley","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2023.112965_bib42","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ejca.2023.112965_bib43","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1200\/JCO.2008.19.9109","article-title":"Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.112965_bib44","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/annonc\/mdr134","article-title":"T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results","volume":"23","author":"Secondino","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.112965_bib45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1479-5876-10-169","article-title":"Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients","volume":"10","author":"Ellebaek","year":"2012","journal-title":"J Transl Med"},{"issue":"8","key":"10.1016\/j.ejca.2023.112965_bib46","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1158\/1078-0432.CCR-12-3702","article-title":"An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma","volume":"19","author":"Le","year":"2013","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:08Z","timestamp":1760733728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923003179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":46,"alternative-id":["S0959804923003179"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112965","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112965","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112965"}}